Literature DB >> 26362747

Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases.

Worawit Louthrenoo1.   

Abstract

Widespread use of immunosuppressive drugs, both conventional disease-modifying antirheumatic drugs (cDMARDs) and biologic disease-modifying antirheumatic drugs (bDMARDs), in autoimmune rheumatic diseases (ARDs) has been found to be associated with the reactivation of underlying latent viruses. The clinical features of virus reactivation can sometimes mimic flare of the underlying ARDs. The correct diagnosis and management of such reactivation is crucial, as increasing the dose of immunosuppressive drugs to treat a presumed flare of underlying ARDs would probably be of no benefit, and it could exert a detrimental effect on the host. This review focused on the effects of immunosuppressive drugs on underlying chronic viral infections, particularly hepatitis B virus, hepatitis C virus, human immunodeficiency virus, varicella zoster virus, Epstein-Barr virus, cytomegalovirus, John Cunningham (JC) virus, Kaposi sarcoma-associated herpesvirus, and human papillomavirus in patients with ARDs. It also covered the effect of interferon-α, which is used to treat chronic hepatitis infection, and the induction of autoimmunity.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-TNFα; Arthritis; Autoimmune rheumatic diseases; Immunosuppressive drugs; Reactivation; Virus

Mesh:

Substances:

Year:  2015        PMID: 26362747     DOI: 10.1016/j.berh.2015.05.010

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  2 in total

Review 1.  Colonic perforation due to severe cytomegalovirus disease in granulomatosis with polyangiitis after immunosuppression.

Authors:  Alessandra Soriano; Nazareno Smerieri; Stefano Bonilauri; Loredana De Marco; Alberto Cavazza; Carlo Salvarani
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

2.  Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients.

Authors:  Polyzois Makras; Panagiotis Petrikkos; Athanasios D Anastasilakis; Artemis Kolynou; Angeliki Katsarou; Olga Tsachouridou; Symeon Metallidis; Maria P Yavropoulou
Journal:  Bone Rep       Date:  2021-09-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.